Showing results (1-10 of 37) with videos related to
Sort By:
Pageof 4
Expert Opinion on Therapeutic Targets|May 1, 2007
Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspectsKonstantinos Drosopoulos, Alexander PintzasBiochimica Et Biophysica Acta|March 25, 2009
Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinicAngeliki Voulgari, Alexander PintzasExpert Opinion on Pharmacotherapy|May 3, 2007
Microarray analysis to reveal genes involved in colon carcinogenesisTobias Joyce, Alexander PintzasBiofactors (Oxford, England)|July 2, 2013
The TRAIL of oncogenes to apoptosisEftychia Oikonomou, Alexander PintzasPlos One|December 31, 2014
EZH2 regulates cofilin activity and colon cancer cell migration by targeting ITGA2 geneAngelo Ferraro, Themis Boni, Alexander PintzasInternational Journal of Cancer|December 22, 2007
Fra-1 regulates vimentin during Ha-RAS-induced epithelial mesenchymal transition in human colon carcinoma cellsChrysovalantis Andreolas, Margarita Kalogeropoulou, Angeliki Voulgari, et al.Oncotarget|November 1, 2014
BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implicationsEftychia Oikonomou, Evangelos Koustas, Maria Goulielmaki, et al.The Journal of Biological Chemistry|June 1, 2002
High activity of serum response factor in the mesenchymal transition of epithelial tumor cells is regulated by RhoA signalingEleni Psichari, Allan Balmain, David Plows, et al.BMC Cancer|August 14, 2016
IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosisPhilippos Perimenis, Apostolos Galaris, Alexandra Voulgari, et al.Plos One|July 9, 2011
Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistanceEftychia Oikonomou, Michal Koc, Vladimira Sourkova, et al.Pageof 4